@Article{IPB-2436, author = {Hussain, H. and Abbas, G. and Green, I. R. and Ali, I.}, title = {{Dipeptidyl peptidase IV inhibitors as a potential target for diabetes: patent review (2015-2018)}}, year = {2019}, pages = {535-553}, journal = {Expert Opin Ther Pat}, doi = {10.1080/13543776.2019.1632290}, url = {https://dx.doi.org/10.1080/13543776.2019.1632290}, volume = {29}, abstract = {Introduction: Dipeptidyl peptidase 4 (DPP-4) belongs to the family of serine proteases and is involved in the degradation of GLP-1 and GIP hormones, which enhance the production and release of insulin. Targeting DPP-4 inhibitors is increasingly being considered as promising paradigms to treat type 2 diabetes mellitus and therefore DPP-4 inhibitors are being considered as promising antidiabetic drugs.Areas covered: This review provides an overview of published patents describing natural and synthetic DPP-4 inhibitors from January 2015 to December 2018.Expert opinion: A fair number of new synthetic and natural DPP-4 inhibitors have been reported in last four years which describe the progress in the development of various heterocyclic scaffolds or heterocyclic hybrid compounds. As a result of this, many marketed DPP-4 inhibitors that have been approved by the appropriate governing bodies during the past decade, have been introduced as inhibitors. Molecular hybridization is an emerging idea in medicinal chemistry and therefore hybrid compounds of DPP-4 inhibitors with other DPP-4 inhibitors or with antidiabetic drugs should be formulated for a comprehensive evaluation. More detailed pharmacovigilance of DPP-4 inhibitors is required because this will address the pancreas-related adverse events as well as their impact on cardiovascular outcomes via long-term studies.} }